Insider Hyep Files Form 4 for Bicara Therapeutics

TL;DR

**Insider Hyep reported a change in Bicara Therapeutics holdings, watch for transaction details.**

AI Summary

Ivan Hyep, a reporting insider, filed a Form 4 on March 24, 2026, indicating a change in beneficial ownership of securities in Bicara Therapeutics Inc. (CIK: 0002023658). While the filing itself doesn't detail specific transactions, it signals that an insider's holdings have changed, which can be a key indicator for investors. This matters because insider activity, especially buying or selling, can reflect their confidence in the company's future performance, influencing how current or potential shareholders view the stock.

Why It Matters

This filing signals a change in an insider's stake in Bicara Therapeutics, which can provide clues about their outlook on the company's future prospects. Investors often monitor such filings for insights into management's confidence.

Risk Assessment

Risk Level: medium — The filing itself doesn't detail the transaction (buy/sell), so the specific impact on risk is currently unknown, but any insider activity carries potential implications.

Analyst Insight

Smart investors should look for the specific transaction details within the full Form 4 document to determine if Hyep Ivan bought or sold shares, and the quantity, to gauge insider sentiment towards Bicara Therapeutics Inc.

Key Players & Entities

• Hyep Ivan (person) — Reporting insider
• Bicara Therapeutics Inc. (company) — Issuer of securities
• 0002034668 (person) — CIK for Hyep Ivan
• 0002023658 (company) — CIK for Bicara Therapeutics Inc.

FAQ

Key Financial Figures

• $18.15 — ple transactions at prices ranging from $18.15 to $18.84, inclusive. The Reporting Per
• $18 — ctions at prices ranging from $18.15 to $18.84, inclusive. The Reporting Person und

Filing Documents

• wk-form4_1774395899.html (4)
• wk-form4_1774395899.xml (4) — 7KB
• 0001628280-26-020876.txt ( ) — 9KB

From the Filing

SEC FORM 4 SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). X Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10. 1. Name and Address of Reporting Person * Hyep Ivan (Last) (First) (Middle) BICARA THERAPEUTICS INC. 116 HUNTINGTON AVENUE, SUITE 703 (Street) BOSTON MASSACHUSETTS 02116 (City) (State) (Zip) UNITED STATES (Country) 2. Issuer Name and Ticker or Trading Symbol Bicara Therapeutics Inc. [ BCAX ] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner X Officer (give title below) Other (specify below) Chief Financial Officer 2a. Foreign Trading Symbol 3. Date of Earliest Transaction (Month/Day/Year) 03/23/2026 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person 4. If Amendment, Date of Original Filed (Month/Day/Year) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 03/23/2026 M (1) 9,200 A $ 3.7898 154,555 D Common Stock 03/23/2026 S (1) 9,200 D $ 18.5161 (2) 145,355 D Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Stock Option (Right to Buy) $ 3.7898 03/23/2026 M (1) 9,200 (3) 04/05/2033 Common Stock 9,200 $ 0 48,944 D Explanation of Responses: 1. This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 13, 2025. 2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.15 to $18.84, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. 3. The shares underlying this option vest in sixteen equal quarterly installments following April 5, 2023, subject to the Reporting Person's continued service on each such vesting date. Remarks: /s/ Lara Meisner, Attorney-in-Fact 03/24/2026 ** Signature of Reporting Person Date Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. * If the form is filed by more than one reporting person, see Instruction 4 (b)(v). ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number. * Form 4: SEC 1474 (03-26)

View Full Filing

View this 4 filing on SEC EDGAR